| Adaptive is comercial-stage company. Co is advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Co.'s clinical diagnostic product, clonoSEQ, is the test authorized by the Food and Drug Administration for the detection and monitoring of minimal residual disease in patients with multiple myeloma and B cell acute lymphoblastic leukemia and is being validated for patients with other blood cancers. Co.'s commercial research product, immunoSEQ, primarily serves as its underlying research and development engine to develop and validate its clinical pipeline. We show 10 historical shares outstanding datapoints in our ADPT shares outstanding history coverage, used to compute ADPT market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADPT market cap history over the course of time is important for investors
interested in comparing ADPT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADPT versus a peer is one thing; comparing
ADPT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADPT can fluctuate over the course of history.
With this page we aim to empower investors researching ADPT by allowing them to research the ADPT market cap history.